]>
IRCT2012101311092N2 IRCT 2012-11-12 Yazd University Of Medical Sciences Effect of Q10 in the treatment of metabolic syndrome Effect of coenzyme Q10 Supplementation on Metabolic Syndrome Parameters, lipid peroxidation, hs-CRP and homocysteine in patients with metabolic syndrome. 2012-10-20 anticipated 60 Complete https://irct.ir/trial/11428 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A Metabolic Syndrome. Intervention 1: Intervention group:Q10,100 mg soft gel capsule twice a day for 3 month. Intervention 2: Placebo group: placebo tablets containing 100 mg of soy oil twice a day for 3 months.
public Dr Gholamreza Usefzadeh
Shariati Ave
Kerman Iran (Islamic Republic of) +98 34 1245 9003 uousefzadeh@kmu.ac.ir Kerman Physiology Research Center scientific Dr Azadeh Najarzadeh
Bahonar Sq
Yazd Iran (Islamic Republic of) +98 35 1623 8505 azmm1383@yahoo.com Shahid Sadoghi University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: 1. Having the metabolic syndrome according to the NCEP ATP III definition: According to the NCEP ATP III definition of having at least 3 of the following conditions: a)Abdominal obesity (waist circumference ≥102 cm in men and≥ 88 cm in women) b) High blood pressure (systolic blood pressure≥130 mm Hg and / or diastolic blood pressure≥85 mm Hg) c)Low HDL-C (< 40 mg/ dl in men and < 50 mg/ dl in women) d)TG ≥150 mg/ dl e)FBS ≥100 mg/ dl 2.Being the age limit from 35 to 55 years 3.Patients with hypertension treated with anti-hypertensive drugs in the past 3 months have not changed and changes in drug therapy not occure during the study period. 4.Patients with diabetes who their treatment in the past 6 weeks has not changed (Changes in drug therapy not occur during the study period ) 5. Consent to participate in the study. Exclusion criteria: 1.Statin use in the last month 2.History of cardiovascular disease in the past three months 3.Having an active infection 4.Risk of renal failure 5.Liver disease (viral hepatitis, treatments for liver disease) 6.Alcohol Consumption 7.Pregnancy or taking contraceptive drugs 8.History of hospitalization in the past 2 months 9.consumption of Nutritional supplements such as vitamins, trace elements, antioxidants 35 years 55 years Both E78.8 Other disorders of lipoprotein metabolism Treatment - Drugs Treatment - Drugs Intervention group:Q10,100 mg soft gel capsule twice a day for 3 month Placebo group: placebo tablets containing 100 mg of soy oil twice a day for 3 months Fasting Plasma Glucose. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzymatic methods. HDL Cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. Blood pressure. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: sphygmomanometer. Waist circumference. Timepoint: at the begining of the study and3 month after intervention. Method of measurement: tape. TG. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzymatic methods. Malondialdehyde. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: thiobarbituric acid method. Hs-CRP. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: ELISA. Homocysteine. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. Total cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. Anthropometric indicators: weight, height, body mass index, waist circumference, hip circumference and waist to hip ratio. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Standard procedures using scale, tape and equations. LDL cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. Yazd University Of Medical Sciences Approved 2012-07-07 Yazd Univesity of Medical Sciences Ethics Committee Bahonar Square Yazd Iran (Islamic Republic of)